Literature DB >> 16835477

[FOLFIRI regimen for metastatic or recurrent colorectal cancer].

Norihisa Uemura1, Yasuhide Yamada.   

Abstract

Irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and Leucovorin (LV) became the standard first-line chemotherapy for colorectal cancer in the U.S. and Europe in 2000, largely owing to the results of controlled randomized phase III trials of 5-FU/LV with or without CPT-11. One of the regimens for CPT-11 plus infusional 5-FU/LV therapy is the FOLFIRI regimen. This regimen consists of CPT-11 180 mg/m(2) as a 90-min infusion on day 1 and l-LV 200 mg/m(2) as a 2-h infusion during CPT-11, immediately followed by a bolus dose of 5-FU 400 mg/m(2) and a 46-h continuous infusion of 2,400 mg/m(2) every 2 weeks. FOLFIRI, as well as oxaliplatin/5-FU/LV therapy (FOLFOX), is an internationally accepted standard chemotherapy for metastatic colorectal cancer. Safe use of this effective regimen requires adequate supportive therapy in Japan, as well as in Western countries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835477

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.

Authors:  Tomohiro Nishi; Yasuo Hamamoto; Etsuko Warita; Junko Miyamoto; Noriyuki Akutsu; Yasuhiro Yamanaka; Michitaka Nagase; Hirofumi Fujii
Journal:  Int J Clin Oncol       Date:  2011-03-18       Impact factor: 3.402

2.  Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.

Authors:  Nozomu Fuse; Toshihiko Doi; Atsushi Ohtsu; Tomonori Yano; Yasuo Hamamoto; Keiko Minashi; Makoto Tahara; Manabu Muto; Masahiro Asaka; Shigeaki Yoshida
Journal:  Int J Clin Oncol       Date:  2008-05-08       Impact factor: 3.402

Review 3.  Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.

Authors:  M Degirmenci; B Karaca; G Gorumlu; R Durusoy; G Demir Piskin; M T Bozkurt; Y Cirak; D Tunali; B Karabulut; U A Sanli; R Uslu
Journal:  Med Oncol       Date:  2009-06-13       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.